studies for the treatment approach were done. A Doppler ultrasound showed: normal arterial fl ow with a post-hepatic artery anastomosis resistance index of 0.61, normal portal and suprahepatic venous flow, and no dilatation of the biliary tract. A pp65 antigenemia assay was done to rule out CMV infection and was negative. Percutaneous biopsy was performed that showed changes consistent with acute cellular rejection (ACR) (Fig. 1 ). Upon admission, 3 boluses of 1 g of methylprednisolone were administered; there was progressive improvement in the liver function tests (LFTs) and upon release they were: ALT 79 U/l, AST 42 U/l, alkaline phosphatase 292 U/l, GGT 1,283 U/l, total bilirubin 2.3 mg/dl, and albumin 3.8 g/dl. The patient was released with immunosuppressive treatment: Prograf™ (tacrolimus) 10 mg every 12 h with residual blood levels of 22 ng/ml, mycophenolate mofetil 1,500 mg every 12 h and prednisone 20 mg per day. Her hospital stay was one week.
Four months after the first ACR episode the patient presented with cytolysis and cholestasis (AST 152 U/l, ALT 223 U/l, alkaline phosphatase 186 U/l, GGT 494 U/l). The patient refused a new liver biopsy. A Doppler ultrasound was done and was normal. Antinuclear antibodies (ANA), IgG, and anti-smooth muscle antibodies were ordered; the ANA test was positive at a dilution of 1:320 with a homogeneous pattern and the IgG was 1.5 N (these studies were normal pre-OLT) and so it was decided to treat the patient for de novo autoimmune hepatitis; her LFTs are currently normal.
The introduction of generic immunosuppressive (IS) medication was approved by the Food and Drug Administration (FDA) in August 2009. 1, 2 In the twenty-fi rst century, tacrolimus is regarded as the immunosuppressant of choice. The patented name of tacrolimus (Prograf™, Astellas Pharma) lost its patent protection in April 2008 and on August 10, 2009, the FDA approved the first generic tacrolimus. 2 In order to be bioequivalent, the generic drug must contain the same quantity of active substance, the same administration route, and the same dose; there should be no signifi cant difference in the rate (maximum concentration) and the concentration of the area under the curve from the reference drug. Generic medications must have a 90% confidence interval and the bioequivalence should be between 80 and 125%. 3 In Mexico the NOM-177-SSA1-1998 guideline establishes the criteria and requisites that must be met when the tests for G. Castillo et al demonstrating the interchangeability of generic medications are carried out, 4 and there are presently 4 brands of oral generic tacrolimus 5 (approved by the COFEPRIS). Factors such as age, race, sex, diet, and metabolism and enteric transport alterations, as well as the polymorphisms of the enzymes that catabolize the IS drugs, can be the source of inter-individual variability. 6 There are different recommendation guidelines for the use of generic drugs in transplantation 7 ; however, the bioequivalence of some of them is still controversial. 2, 8, 9 In a study conducted in Mexico, 3 different brands of generic tacrolimus were compared with the innovative substance (Prograf™). It was found that they were not bioequivalent to Prograf™. 9 Nevertheless, even though they do not have the same bioequivalence, other studies have shown them to be effective and safe for use. 10 Generic medications can be a useful and effi cacious option in the treatment of transplantation patients. However, not all generic medication presentations have demonstrated bioequivalence and bioavailability. Moreover, there can be important differences among the different brands of generic IS drugs. Individual dose adjustment is crucial when using generic IS medications, not only for preventing acute rejection, but also for prolonging patient and graft survival.
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